Limits...
Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome – induced hypophosphatemia

View Article: PubMed Central - PubMed

ABSTRACT

Fibroblast growth factor 23 (FGF23) is regulated by sustained phosphate supplementation and restriction. However, few studies have investigated FGF23 levels in patients with Fanconi syndrome. Therefore, we evaluated intact and C-terminal FGF23 and FGF23-associated parameters in four patients with Fanconi syndrome. Serum intact and C-terminal FGF23 levels were extremely low. Although serum phosphate and 1,25-dihydroxyvitamin D levels improved to or above the normal range within 1 year of treatment with oral phosphate and calcitriol, serum FGF23 levels remained low. Serum FGF23 levels in patients with Fanconi syndrome might be regulated by novel factors other than serum phosphate and 1,25-dihydroxyvitamin D levels.

No MeSH data available.


Related in: MedlinePlus

Changes in parameters associated with CKD–mineral and bone disorder.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5036911&req=5

SFW086F2: Changes in parameters associated with CKD–mineral and bone disorder.

Mentions: Changes in other parameters associated with CKD–mineral and bone disorder are shown in Figure 2. Phosphate and 1,25-dihydroxyvitamin D levels increased to normal or above-normal levels. TmP/GFR and estimated GFR increased in patients 1, 3 and 4, but did not change in patient 2, as the patient refused treatment for Fanconi syndrome. Alkaline phosphatase (ALP) levels decreased in all cases, but were still above the normal range after 1 year. Serum calcium levels did not change during the follow-up period, despite the administration of the appropriate therapy for 1 year.Fig. 2.


Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome – induced hypophosphatemia
Changes in parameters associated with CKD–mineral and bone disorder.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5036911&req=5

SFW086F2: Changes in parameters associated with CKD–mineral and bone disorder.
Mentions: Changes in other parameters associated with CKD–mineral and bone disorder are shown in Figure 2. Phosphate and 1,25-dihydroxyvitamin D levels increased to normal or above-normal levels. TmP/GFR and estimated GFR increased in patients 1, 3 and 4, but did not change in patient 2, as the patient refused treatment for Fanconi syndrome. Alkaline phosphatase (ALP) levels decreased in all cases, but were still above the normal range after 1 year. Serum calcium levels did not change during the follow-up period, despite the administration of the appropriate therapy for 1 year.Fig. 2.

View Article: PubMed Central - PubMed

ABSTRACT

Fibroblast growth factor 23 (FGF23) is regulated by sustained phosphate supplementation and restriction. However, few studies have investigated FGF23 levels in patients with Fanconi syndrome. Therefore, we evaluated intact and C-terminal FGF23 and FGF23-associated parameters in four patients with Fanconi syndrome. Serum intact and C-terminal FGF23 levels were extremely low. Although serum phosphate and 1,25-dihydroxyvitamin D levels improved to or above the normal range within 1 year of treatment with oral phosphate and calcitriol, serum FGF23 levels remained low. Serum FGF23 levels in patients with Fanconi syndrome might be regulated by novel factors other than serum phosphate and 1,25-dihydroxyvitamin D levels.

No MeSH data available.


Related in: MedlinePlus